Cleveland Diagnostics Adds Dara Grantham Wright to Board of Directors
23 Julio 2024 - 6:53AM
Business Wire
Wright Brings Broad Healthcare and Diagnostics
Expertise to Biotech’s Board; Current CEO of Madison Industries
Medical Division & Previous EVP of Clinical Diagnostics at
Bio-Rad
Cleveland Diagnostics, Inc., a cancer biotechnology company,
today announced the appointment of a new independent director, Dara
Grantham Wright, to its Board of Directors. Wright’s extensive
experience in life science research and clinical diagnostics will
be an asset to Cleveland Diagnostics as it expands
commercialization of its IsoPSA® prostate cancer test, and brings
new products to the market.
Wright is a growth-oriented leader with a demonstrated track
record of building commercial success in the life sciences and
clinical sectors with direct experience in both the Clinical
Laboratory and In Vitro Diagnostics (IVD) environments. She’s held
successively senior executive leadership positions at several
leading organizations, including Bio-Rad, Thermo Fisher Scientific,
and Becton Dickinson.
“I am honored to join the Board of Directors at Cleveland
Diagnostics,” said Wright. “I look forward to supporting their
mission of expanding access to leading-edge diagnostic tests to
significantly enhance early cancer detection.”
Wright is joining a board currently comprising Noel Jee of Novo
Holdings, Sameer Rohatgi of Lyfe Capital, Joe Rich of Cleveland
Clinic, and Cleveland Diagnostics’ CEO Arnon Chait.
“I am very pleased to have Dara join our Board,” shared Arnon
Chait, PhD, company president and CEO. “Dara’s extensive hands-on
experience in scaling up both small and large companies in the
diagnostics space will be incredibly valuable as Cleveland
Diagnostics navigates commercializing our unique, highly accurate
cancer tests – especially as we explore new therapeutic areas with
our proprietary platform, IsoClear™. I am eager to have Dara
contribute to our future and look forward to working closely with
her.”
Wright’s appointment follows a growth equity financing earlier
this year, through which Cleveland Diagnostics successfully secured
$75M in financing to advance the development of its proprietary
structure-focused early cancer detection testing platform,
IsoClear. The company’s R&D team continues to actively explore
the potential of IsoClear in other disease states to build a new
class of clinical laboratory tests that help deepen clinical
insights and reduce unnecessary, invasive procedures for
patients.
For more information and company news, visit ClevelandDx.com
About Cleveland Diagnostics, Inc.
Cleveland Diagnostics is a breakthrough cancer biotechnology
company that is changing the shape of cancer detection. The company
has unlocked the diagnostic power of protein structure with its
revolutionary IsoClear™ platform that enables novel diagnostics
based on a single cancer-specific, protein structure-based
assessment using easy to execute tests within the clinical lab
setting. Learn more at ClevelandDx.com and IsoPSA.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723788229/en/
Media Contact: Liz Robinson News@ClevelandDx.com (312)
997-2436
Investor Contact: David Holmes IR@ClevelandDx.com (332)
330-1031